DOH cautions against overpriced COVID drugs

The Department of Health on Friday warned against overpricing an investigational drug used on COVID-19 patients.

The department said a 100-milligram vial of remdesivir must only cost P1,500 to P8,200.

The department, in its warning, cited a joint administrative order with other government agencies that those “found to have committed any illegal act of price manipulation would be penalized administratively and criminally.”

The Philippines continues to battle a surge in COVID-19 infections that health authorities have attributed to new coronavirus variants, increased mobility and relaxed adherence to health protocols.

The department advised the public to send complaints on overpriced remdesivir to [email protected]

The department also said the use of the investigational drug required a compassionate use permit from the Food and Drug Administration.

The country’s supply of remdesivir and tocilizumab, another drug also used on COVID-19 cases, was replenished last month after a shortfall.

Topics: Department of Health , COVID-19 , remdesivir , Food and Drug Administration
COMMENT DISCLAIMER: Reader comments posted on this Web site are not in any way endorsed by Manila Standard. Comments are views by readers who exercise their right to free expression and they do not necessarily represent or reflect the position or viewpoint of While reserving this publication’s right to delete comments that are deemed offensive, indecent or inconsistent with Manila Standard editorial standards, Manila Standard may not be held liable for any false information posted by readers in this comments section.